pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 37 Non-oncology: 26
Oncology: 11
Under Consideration for Negotiation 18 Non-oncology: 9
Oncology: 9
Completed Negotiations 853 With Letter of Intent: 741
Without agreement: 112
Negotiations That Were Not Pursued 111

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Tysabri Biogen Canada Inc. Multiple Sclerosis, Relapsing-Remitting
Mavenclad EMD Serono Canada, a division of EMD Inc. Multiple Sclerosis, Relapsing-Remitting
Wegovy Novo Nordisk Canada Inc. Weight Management
Dupixent Sanofi-Aventis Canada Inc. Severe chronic rhinosinusitis with nasal polyps
Dupixent Sanofi-Aventis Canada Inc. Prurigo nodularis
Tagrisso AstraZeneca Canada Inc. ​For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in co
Signifor LAR Recordati Rare Diseases Canada Inc. Acromegaly in Adults
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Oslya Mantra Pharma Multiple Indications
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.​
Rezurock Sanofi-Aventis Canada Inc. Chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older, after failure of at least two prior lines of systemic therapy.
Blincyto Amgen Canada Inc. Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.
Blincyto Amgen Canada Inc. For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.
Ojjaara GlaxoSmithKline Inc. For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.
Hemgenix CSL Behring Canada Inc. Hemophilia B
Noyada Ethypharm Inc. Multiple Indications

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks